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doi:10.1016/j.jtcvs.2007.04.018bjectives: Pleomorphic carcinoma of the lung, a rare malignant disease with a
ual-cell component of spindle and/or giant cells, and of epithelial cells, was defined
n the World Health Organization classification updated in 1999. Reported prog-
oses are heterogeneous, and optimal treatment remains undefined.
ethods: Data were retrospectively examined for 45 consecutive patients (41 men
nd 4 women) who had undergone surgical resection for pulmonary pleomorphic
arcinoma.
esults: Sarcomatous elements were as follows: 23 spindle cell types (51.1%), 11
iant cell types (24.4%), and 11 combined spindle and giant cell types (24.4%).
pithelial components were adenocarcinoma in 25 (55.6%) patients, squamous cell
arcinoma in 8 (17.8%) patients, and large call carcinoma in 12 (26.7%) patients.
odal status was classified as pN0 disease in 28 (62.2%) patients, pN1 disease in 5
11.1%) patients, and pN2 disease in 12 (26.7%) patients. Even patients with pN0
isease frequently manifested vascular invasion (16/28 [57.1%]). Five-year overall
urvival and disease-free survival were 39.2% and 47.1%, respectively. Although
he subtype of epithelial components, as well as sarcomatous elements, did not
ffect prognosis, overall survival (P  .02) and disease-free survival (P  .002) in
atients with pN1/N2 disease were significantly worse than those in patients with
N0 disease. Most recurrences occurred at distant sites (14/20 [70.0%]), and
ecurrence within 6 months after resection was found in 10 patients (10/20 [50.0%]).
oreover, median survival time after confirmation of initial relapse was 2.6 months.
onclusions: Pulmonary pleomorphic carcinoma, which often presented in symp-
omatic male smokers as a large peripheral lesion, carried a poor prognosis, even
hen early-stage disease was diagnosed and resected. Distant metastases occurred
ore frequently and earlier, and the survival after relapse was very short, suggesting
hat this entity should be considered to have a tremendously aggressive malignant
ehavior. Further investigation of biologic features of pulmonary pleomorphic
arcinoma and therapeutic response is a high-priority issue, so that suitable treat-
ent strategies can be planned.
he presence of sarcomatoid or pleomorphic elements with spindle or giant
cells is an infrequent but well-recognized characteristic of some non–small
cell lung cancers (NSCLCs). Before 1999, pathologists confronted with such
umors repeatedly experienced difficulties in providing a definite diagnosis, mainly
ecause of the lack of standardization in terminology and diagnostic criteria. In the
orld Health Organization classifications revised in 1999, a group of poorly
ifferentiated NSCLCs that have sarcomatous or sarcoma-like elements are de-
cribed. Examples of pleomorphic carcinoma are NSCLC; squamous cell carci-
oma; adenocarcinoma; large-cell carcinoma containing spindle cells, giant cells, or
oth; or a carcinoma consisting only of spindle cells and giant cells.1,2 The
leomorphic component should comprise at least 10% of the neoplasm. Giant cell
arcinoma is restricted to a malignancy that is exclusively composed of giant cells,
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TSnd spindle cell carcinoma is limited to that constituted of
nly spindle cells. Most fall into the category of pleomor-
hic carcinomas because of the presence of a double-cell
omponent, and their pure forms are extremely uncomm3
The actual nature of pleomorphic carcinoma has been
ebated extensively because of its rarity. In particular, its
alignant grade and clinical behavior have not yet been
efined. Two conflicting results are available on prognosis.
ome investigations reported pleomorphic carcinoma to
ave a more aggressive clinical course and significantly
oorer survival in comparison with other NSCLCs,4,5 but
thers failed to demonstrate any poorer prognosis for pleo-
orphic carcinomas.3,6 Several case reports but very f
tudies have been published regarding surgical resection of
ulmonary pleomorphic carcinomas. However, to verify the
roper selection of treatment strategy for this tumor, an
nderstanding of its clinicopathologic behavior and prog-
osis is crucial. In view of the rarity and the significance of
he histologic diagnosis, this study was accomplished in a
etrospective, two-institutional setting with a critical review
f pathology by an expert panel. We examined the clinico-
athologic features of patients with pulmonary pleomorphic
arcinoma and extensively analyzed surgical outcome.
aterials and Methods
e retrospectively examined data on 45 patients (41 men and 4
omen) with lung pleomorphic carcinoma who underwent surgi-
al resection between March 1985 and August 2006. Medical
ecords provided information on age, sex, presenting symptom,
moking habits, stage, and operation. Bronchoscopy was per-
ormed preoperatively to establish the diagnosis of malignancy and
o determine the extent of invasion and adequacy of the remaining
irway. Preoperative evaluation included physical examination,
hest roentgenography, and tumor markers. Furthermore, contrast-
nhanced computed tomographic scans of the chest, abdomen, and
rain and bone scintigraphy were executed routinely. Staging was
one based on the new International Staging System for Lung
ancer.7
The standard surgical technique was used and accompanied by
outine systematic dissection or sampling of the hilar and medias-
inal nodes in every case. Intraoperative frozen examination was
one to determine the extent of resection and to assess nodal status.
fter surgical intervention, the patients were examined in the
utpatient clinic at 3-month intervals for 3 years and thereafter at
-year intervals in general. Two dedicated pulmonary pathologists
xamined all specimens histopathologically and classified them
ccording to the criteria set by the World Health Organization.
arcomatoid components were classified as follows: spindle cell
ype, giant cell type, and the combined spindle and giant cell type.
Abbreviation and Acronym
NSCLC non–small cell lung cancerpithelial elements were described also. An institutional review s
00 The Journal of Thoracic and Cardiovascular Surgery ● Auguoard approved this retrospective study, and written informed
onsent for the surgical intervention was obtained from each
atient.
The duration of overall survival was defined as the interval
etween the day of the operation and the date of death by any
ause or the last follow-up date. Disease-free survival was the
nterval from the date of resection to the date of proved detection
f recurrence or metastases. Distributions of disease-free interval
nd overall survival were estimated by using the Kaplan–Meier
ethod and compared by using the log–rank test.
esults
linicosurgical characteristics of the tumor are demon-
trated in Table 1. Patient age ranged from 39 to 80
mean, 65.8 years), and the male/female ratio was 10.3:1.
hirty-eight (84.4%) patients were smokers. The main clin-
cal symptoms at presentation were chest pain (n  6) and
ever (n  6). Tumor size ranged between 23 and 170 mm
mean, 50.1 mm). In most cases the tumor was located in the
pper lobes (n  33 [73.3%]; right, 20; left, 13). Except for
cases, all tumors were located in peripheral parenchyma
n  41 [91.1%]). Preoperative pathologic assessment in-
icated adenocarcinoma in 20 patients, squamous cell car-
inoma in 8 patients, large cell carcinoma in 4 patients, and
ndefined non–small cell carcinoma in 13 patients, demon-
trating that we failed to make the exact diagnosis before
urgical intervention in all the patients. Neoadjuvant che-
otherapy was administered to 1 patient, and chemoradio-
herapy was administered to 1 patient, but downstaging of
he disease was not achieved in either patient. Surgical
rocedures included 39 lobectomies, 2 peumonectomies, 2
able 1. Clinicosurgical characteristics (n  45)
Factor
Age (y)
Range 39-80
Mean 65.8
Sex
Male 41
Female 4
Smoking status
Smoker (current/former) 38 (16/22)
Nonsmoker 7
Size of tumor (mm)
Range 23-170
Mean 50.1
Procedure
Pneumonectomy 2 (4.4%)
Lobectomy 39 (86.7%)
 Bronchoplasty 6
 Extended resection 19
Segmentecomy 2 (4.4%)
Wedge resection 2 (4.4%)egmentectomies, and 2 wedge resections. Among the 39
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G
TSobectomies, 6 bronchoplastic procedures were carried out,
nd 19 extended resections were required because of inva-
ion of the adjacent tissue, including muscle and rib (n 
3), parietal pleura (n  2), diaphragm (n  2), and vagal
erve (n  2). Interlobar invasion was observed in 3 pa-
ients. Complete resection (R0) was achieved in 39 (86.7%)
atients, and a microscopic positive resection margin (R1)
as observed in 6 (13.3%) patients, although no patient had
macroscopic incomplete resection.
Sarcomatous elements and epithelial components are
hown in Table 2. Pathologic stages were as follows: 
A in 5 patients, stage IB in 9 patients, stage IIB in 16
atients, stage IIIA in 10 patients, stage IIIB in 3 patients,
nd stage IV in 2 patients. Nodal status was classified as
N0 in 28 (62.2%) patients, pN1 in 5 (11.1%) patients, and
N2 in 12 (26.7%) patients (Table 3). Microscopic i
ions into the blood vessels were observed in 29 patients
able 2. Stage and histopathology (n  45)
Factor
Clinical stage
IA 5 (11.1%)
IB 16 (35.6%)
IIA 2 (4.4%)
IIB 14 (31.1%)
IIIA 7 (15.6%)
IIIB 1 (2.2%)
IV 0
Pathologic stage
IA 5 (11.1%)
IB 9 (20.0%)
IIA 0
IIB 16 (35.6%)
IIIA 10 (22.2%)
IIIB 3 (6.7%)
IV 2 (4.4%)*
Sarcomatous elements
Spindle 23 (51.1%)
Giant 11 (24.4%)
Spindle and giant 11 (24.4%)
Epithelial components
Adenocarcinoma 25 (55.6%)
Squamous cell carcinoma 8 (17.8%)
Large cell carcinoma 12 (26.7%)
Pulmonary metastases were identified in the other lobes.
able 3. Vascular invasion, lymphatic permeation, and
odal status
odal status Vascular invasion Lymphatic permeation
N0 (n  28) 16 (57.1%) 4 (14.3%)
N1 (n  5) 2 (40.0%) 1 (20.0%)w
N2 (n  12) 11 (91.7%) 10 (83.3%)
The Journal of Thoracic29/45 [64.4%]), and permeations of lymphatic vessels were
ound in 15 patients (15/45 [33.3%]). Even patients with
N0 disease frequently had vascular invasion (16/28
57.1%]). Neither severe postoperative complications nor
n-hospital mortality, including 30-day operative mortality,
ccurred in this series.
Median follow-up was 37 months. Three-year and 5-year
verall survivals were 48.6% and 39.2%, respectively (
re 1, A), whereas disease-free survival was 51.9% a
ears and 47.1% at 5 years (Figure 1, B). There wer
tatistically significant differences between the pN0 and
N1/N2 groups in overall survival (P  .02) and disease-
ree interval (P  .002, Figure 2). The subtype of epithe
omponents or sarcomatous elements did not affect overall
urvival or disease-free interval (Figures 3 and 4). Am
0 patients with recurrent disease, 14 (70.0%) initially had
istant metastasis, and 6 (30.0%) had locoregional relapse
Table 4). The major sites of metastasis firstly ident
igure 1. Overall survival curve (A) and disease-free interval
B) for surgically resected pleomorphic carcinoma.ere bone (6/14 [42.9%]) and brain (4/14 [28.6%]). All the
and Cardiovascular Surgery ● Volume 134, Number 2 401
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G
TSistant metastases developed within 14 months after the
peration, which included 8 patients with pN0 disease (8/14
57.1%]). Surprisingly, early postoperative relapse within 6
onths was found in 10 patients (10/20 [50.0%]), and
urthermore, overall survival after confirmation of the initial
elapse was 23.5% at 6 months, with a median survival time
f 2.6 months.
iscussion
he true incidence of pulmonary pleomorphic carcinoma is,
n all probability, low, although it has not been well defined.
n our series 1.6% (45/2743) of resected NSCLCs were
leomorphic carcinomas. The majority of patients given
iagnoses of pulmonary pleomorphic carcinoma were male
nd smokers who presented with symptoms, which is sim-
lar to patients in earlier studies.4,8,9 The pleomorphic car-
inomas in this study, which ranged from 23 to 170 mm,
igure 2. Overall survival curve (A) and disease-free interval
B) for surgically resected pleomorphic carcinoma according to
athologic nodal status.ith an average greatest dimension of 50 mm, tended to be d
02 The Journal of Thoracic and Cardiovascular Surgery ● Auguarge peripheral tumors. Because of a relatively large tumor
otentially invading adjacent tissue, patients clinically pre-
ented with tumor-related symptoms, such as chest pain.
ossi and coworkers9 reported that cough, hemoptysis, 
oth were the most common presenting symptoms, occur-
ing in 80% of patients, and that only 6.7% of patients had
o symptoms at presentation. According to Fishback and
olleagues,4 65% of pleomorphic carcinomas were locat
n the upper lobes, 47% were in the right upper lobes, 60%
ere peripheral masses, and 24% had invaded the chest
all. Those findings were nearly consistent with those in
ur series. We note a predilection for the upper lobes, as in
arlier series.10,11 Our data demonstrated that preoperati
athologic diagnosis in tiny tissues was complicated, which
eemed to be caused by the heterogeneity and poor differ-
ntiation of the tumor cells. As a result, a definite diagnosis
as finally established based on examination of surgically
esected specimens. Also, the biphasic appearance of the
umor often makes diagnosis so difficult that immunohisto-
hemical examination could be helpful in appropriate
igure 3. Overall survival curve (A) and disease-free interval
B) for surgically resected pleomorphic carcinoma according to
arcomatous elements.iagnosis.12
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G
TSThe clinical behavior and prognosis of pleomorphic car-
inoma have seldom been discussed. Some reports showed
worse prognosis for patients with pleomorphic carcinoma
ompared with that of patients with other variants of
SCLCs,4,5 whereas Nakajima and associates6 reported
imilar clinical behaviors and prognosis between the 2
roups.3 The most important implication of the pres
tudy is the determination of the malignant grade of this
ntity. The overall survival of patients with pathologic N0
leomorphic carcinoma was 55% at 5 years, which was
efinitely worse than that of all patients with pathologic N0
SCLCs (73% at 5 years).13 Also, the presence of path-
ogic nodal involvement negatively affected overall survival
nd disease-free interval, whereas interestingly, the subtype
f epithelial components or sarcomatous elements did not
nfluence prognosis. Patients with pN0 disease frequently
ad vascular invasion (57.1%), indicating that distant me-
astases often occurred, even in early-stage disease. To our
urprise, we found that almost half of all patients and one
igure 4. Overall survival curve (A) and disease-free interval
B) for surgically resected pleomorphic carcinoma according to
pithelial components.hird of patients with pN0 disease had died within 18
The Journal of Thoraciconths of the operation and that almost half of all patients
nd a third of patients with pN0 disease had a recurrence
ithin 14 months. These disappointing data suggest that
ulmonary pleomorphic carcinoma might be fatal, even at
n early stage, unlike other NSCLCs. Notably, among 20
atients with relapse, including 8 patients with pN0 disease,
9 patients had recurrent disease within 14 months after the
peration (95.0%), and moreover, 6-month survival after
nitial proof of postoperative recurrence was a miserable
3.5%. These results showed that pleomorphic carcinoma
ight be extremely aggressive in contrast with other
SCLCs.
The limitation of the present study should be mentioned:
nalysis in resectable cases to make sure that a methodical
xamination of pathologic characteristics would be possi-
le. Therefore advanced unresectable lesions were inevita-
ly excluded. Future investigations should incorporate ad-
anced disease, even though it is difficult to obtain sufficient
pecimens by using biopsy samples and to make a definitive
iagnosis in patients without surgical intervention. Results
f this study showed difficulties in achieving a preoperative
iagnosis. Pleomorphic carcinoma has been recognized as a
orm of NSCLC, and at present, the therapeutic strategy is
he same as that for cases of NSCLC. Little information is
vailable on systemic treatment options for this tumor en-
ity, but basically, chemotherapy is considered ineffective
ecause of the experienced poor sensibility of these types of
umors. Because of poor prognosis, combination of exten-
ive surgical intervention resection with aggressive postop-
rative chemotherapy, radiotherapy, or both might be a
easonable consideration to improve survival. Further large-
cale assessment of the therapeutic response of pleomorphic
arcinoma, including that to surgical intervention, chemo-
herapy, or radiation, is a high-priority issue that will deter-
ine the planning of appropriate treatment strategy.
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